Avivagen Stock Return On Equity
| VIVXF Stock | USD 0.0001 0.00 0.00% |
Avivagen fundamentals help investors to digest information that contributes to Avivagen's financial success or failures. It also enables traders to predict the movement of Avivagen Pink Sheet. The fundamental analysis module provides a way to measure Avivagen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avivagen pink sheet.
Avivagen |
Avivagen Company Return On Equity Analysis
Avivagen's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Avivagen has a Return On Equity of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
Avivagen Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avivagen's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Avivagen could also be used in its relative valuation, which is a method of valuing Avivagen by comparing valuation metrics of similar companies.Avivagen is currently under evaluation in return on equity category among its peers.
Avivagen Fundamentals
| Return On Asset | -0.95 | |||
| Operating Margin | (12.34) % | |||
| Current Valuation | 9.01 M | |||
| Shares Outstanding | 77.19 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Price To Sales | 11.96 X | |||
| Revenue | 1.3 M | |||
| Gross Profit | 534.34 K | |||
| EBITDA | (4.68 M) | |||
| Net Income | (6.39 M) | |||
| Cash And Equivalents | 494.81 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.4 M | |||
| Current Ratio | 0.81 X | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (4.6 M) | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 13 | |||
| Beta | 0.74 | |||
| Market Capitalization | 5.2 M | |||
| Total Asset | 3.48 M | |||
| Z Score | -1.5 | |||
| Net Asset | 3.48 M |
About Avivagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avivagen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avivagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avivagen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Avivagen Pink Sheet
Avivagen financial ratios help investors to determine whether Avivagen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avivagen with respect to the benefits of owning Avivagen security.